Novartis, Egypt’s Cleopatra Hospitals Group ink pact for cardiovascular disease treatment

EGYPT – Pharma giant Novartis Pharma Egypt and Cleopatra Hospitals Group (CHG), Egypt’s best provider of medical and healthcare services, have entered into a strategic partnership deal to provide the best healthcare services to atherosclerotic cardiovascular disease (ASCVD) patients.

Country President of Novartis Pharma Egypt Dr. Sherif Amin signed the agreement on behalf of the pharmaceutical giant while Dr. Ahmed Ezz El-Din who is the Managing Director of Cleopatra Group signed on behalf of the hospital group.

In addition, Head of PAteint Access, Innovative Medicines Division at Novartis Pharma Egypt Dr. Ali Omar and Dr. Ahmed Abdel Rahman Sharaf, Consultant Cardiologist and Head of Cardiology Department for Cleopatra Hospitals Group were involved with witnessing the signing ceremony.

We aim , through the new cooperation , to work quickly to reach an innovative treatment for patients with atherosclerosis in Egypt and provide long-term solutions to achieve early diagnosis of patients with atherosclerosis of the heart and blood vessels

Dr. Ali Omar, Head of Patient Access, Innovative Medicine Division at Novartis Pharma Egypt Tweet

Under the deal, Novartis Pharma Egypt and Cleopatra Hospitals Group will provide ideal care for cardiovascular disease patients such as providing the latest treatments and the best possible services throughout their treatment.

The collaboration further builds on the ongoing collaboration between Novartis Pharma Egypt, one of the leading medicines companies supporting the Egyptian patient, and Cleopatra Hospitals Group, which has a great history of providing healthcare services in Egypt.


Country President of Novartis Pharma Egypt Dr. Sherif Amin reassured the multinational company’s clear and steadfast commitment to supporting patients and its relentless work to provide cutting-edge medications.

Partnering with all health sectors in Egypt is one of our most important priorities as we seek to provide innovative medicines on a large scale throughout Egypt specifically through patient support programs and partnerships with various entities to develop the health sector in Egypt,” he explained.

Dr. Sherif Amin revealed that Novartis has announced six new medications throughout this year as part of its strategy to promote patient health in Egypt, noting that the business is striving to boost Egypt’s pharmaceutical industry amid the ongoing COVID-19 pandemic.

He stressed that programs can be built around shared goals and contributions that create value for the healthcare providers as well as the communities the company serves, adding that Novartis is willing to participate in any medical or scientific endeavors that aim to enhance the medical environment in Egypt.

CEO Cleopatra Hospitals Group Dr. Ahmed Ezz El-Din stressed that the collaboration between Cleopatra Group and Novartis aims to achieve the common goal of accelerating access to innovative treatments to the atherosclerotic cardiovascular disease patient.

The collaboration between Cleopatra Group and Novartis aims to radically improve outcomes through secondary prevention for patients who have already received treatment for heart attacks and creating long-term solutions that provide early diagnosis for patients with ASCVD,” Ezz El-Din pointed out.

The Managing Director of Cleopatra Group further said that the cardiovascular system enables qualified patients to have early access to the cutting-edge treatment that Novartis offers in line with the hospital Group’s motto of “Excellence in Healthcare”.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.